ClinicalTrials.gg
CompletedNCT07940790Updated Nov 17, 2026

A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily, With the Dose Chosen According to Blood Pressure at Enrollment as in Routine Practice, Over 9 Months in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.

An interventional study of Olmesartan in Type 2 Diabetes Mellitus, Diabetic Kidney Disease and Albuminuria, sponsored by Tri-Service General Hospital (TSGH). Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Tri-Service General Hospital (TSGH) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Oct 2022, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing olmesartan in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. olmesartan · Diabetes Mellitus, Type 2.

Enrollment
10th of 10
60 · median 254
Started
2022
the only one that year
No phase
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
Tri-Service General Hospital (TSGH)

Among the 10 studies testing olmesartan in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is the only one that started in 2022, is the only one with no phase, and was the 10th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 10 studies testing olmesartan in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About olmesartan

olmesartan: first FDA approval 2002 (BENICAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing olmesartan in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of adding olmesartan to sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in patients with type 2 diabetes mellitus and persistent albuminuria. Participants receive olmesartan at a dose of either 20 mg or 40 mg daily in addition to their ongoing SGLT2i treatment. Changes in urinary albumin-to-creatinine ratio (UACR), renal function, and blood pressure are assessed over a 9-month follow-up period. The study aims to evaluate the potential additional renoprotective effects of olmesartan in patients with type 2 diabetes who continue to have albuminuria despite SGLT2i therapy.

Read the detailed description

Diabetic kidney disease is a major complication of type 2 diabetes mellitus. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide established cardiorenal protection, residual albuminuria may persist in some patients despite ongoing treatment.

Olmesartan, an angiotensin II receptor blocker (ARB), reduces intraglomerular pressure and albuminuria through inhibition of the renin-angiotensin system.

This single-center, open-label pilot study evaluates the effects of adding olmesartan at 20 mg or 40 mg daily to ongoing SGLT2i therapy in patients with type 2 diabetes and albuminuria. Renal parameters, including urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and serum creatinine, as well as blood pressure and safety parameters, are assessed during a 9-month follow-up period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Diabetic Kidney Disease
  • Albuminuria
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults with type 2 diabetes mellitus. Patients receiving ongoing sodium-glucose cotransporter-2 inhibitor therapy. Patients with persistent albuminuria who meet the study-defined eligibility criteria.

Patients who are willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

Known or history of severe adverse reactions to other angiotensin receptor blockers (ARBs).

Active liver disease or severe hepatic impairment ( [AST] > 3 × [upper limit of normal]; Alanine transaminase [ALT] > 3 × ULN).

Moderate-to-severe renal impairment (estimated \< 30 mL/min/1.73 m²). Women who are pregnant or currently breastfeeding. Judged by the study investigator to be unsuitable for participating (or continuing) in this trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Olmesartan 20 mg

    Participants receive olmesartan 20 mg orally once daily in addition to their ongoing SGLT2 inhibitor therapy.

    Drug: Olmesartan

  • Experimental
    Olmesartan 40 mg

    Description: Participants receive olmesartan 40 mg orally once daily in addition to their ongoing SGLT2 inhibitor therapy.

    Drug: Olmesartan

Interventions

  • Olmesartan is administered orally once daily at a dose of 20 mg or 40 mg, according to the assigned study group, as add-on therapy to ongoing sodium-glucose cotransporter-2 inhibitor treatment. Treatment is continued during the 9-month study period.

06

What researchers measure

Primary outcomes

  1. Percentage Change in Urinary Albumin-to-Creatinine Ratio (UACR) from Baseline to Month 9

    The percentage change in urinary albumin-to-creatinine ratio (UACR) from baseline to 9 months after initiation of olmesartan treatment. UACR is measured using urine albumin and creatinine concentrations.

    Time frame: Baseline to Month 9

Secondary outcomes

  1. the dose-comparison outcome was a ≥30% UACR reduction at 9 months.

    the dose-comparison outcome was a ≥30% UACR reduction at 9 months.

    Time frame: Baseline to Month 9

07

Study locations

1 site
  • Tri-Service General Hospital
    Taipei, 114202, Taiwan
08

References and documents

Individual participant data

Plan to share: No — The datasets generated and/or analyzed during the current study are not publicly available due to patient privacy and ethical restrictions imposed by the Institutional Review Board of Tri-Service General Hospital. However, de-identified data are available from the corresponding author upon reasonable request and with prior approval from the ethics committee.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Dec 2023, 14 months.

Of 2,070 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 14 months is below that.

Counting every sponsor, half of 2,247 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Oct 26, 2022
Primary completionActual
Dec 29, 2023
CompletionActual
Mar 16, 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940790
Lead sponsor
Tri-Service General Hospital (TSGH)
Responsible party
Chieh-Hua Lu (Attending Physician, Tri-Service General Hospital (TSGH)) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 26, 2022
Primary completion
Dec 29, 2023
Completion
Mar 16, 2024
Last update
Nov 17, 2026

Study contacts

Chieh-Hua Lu
principal investigator · Tri-Service General Hospital (TSGH)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olmesartan

Start the discussion